Insider buying last 90 days
No open-market insider purchases were filed for ORKA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Oruka Therapeutics reported third quarter 2026 financial results this week, with EVERLAST-B Week 16 data showing 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, described as highly consistent with EVERLAST-A. The company also announced participation in multiple upcoming conferences. Separately, a filing showed Candriam S.C.A. trimmed its ORKA holdings by 3.9% during the third quarter.
ORKA closed at $104.56, up 1.7%, sitting above both its 50-day average of $88.48 and its 200-day average of $71.21, with the 50-day above the 200-day. The GekkoIndex reads 45.6, placing the stock in the Neutral zone, down 3.8 over five days. Gekko Fair Value stands at $107.52, putting price 2.8% below that mark.
Oruka's next earnings report is scheduled for 11 November 2026, just 116 days away and within a typical 20-trading-day hold; the prior quarter's report produced a 5.9% reaction, with 5 beats across 8 quarters. No insider, Congress or unusual options activity appears in the current windows, though one billionaire holder and one trailblazer holder are noted. Analyst coverage from 11 firms is unanimously rated buy, with a consensus target of $156.17. Seasonality from this point has averaged -5.1% over the next 20 trading days across 5 years, rising in 2 of them, a pattern worth noting given the imminent earnings date.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Oruka Therapeutics scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $105.35 is above the 50-day ($89.68) and 200-day ($72.65) averages, and the 50-day is above the 200-day.
See the chart48.2, Neutral
Reading 48.2 is in the Neutral zone.
See the GekkoIndex2.8% below
Price is within 5% of Gekko Fair Value (2.8% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 116 days
Next report Mar 11, 2027, 116 days away — outside a typical 20-trading-day hold.
See earnings+0.2% on average
From this point in the calendar, the next 20 trading days averaged +0.2% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Oruka Therapeutics closed at $105.35 on Nov 13, 2026, +272.3% over the past year, inside a 52-week range of $25.23 to $115.52.
Use the left and right arrow keys to read daily values.
Put ORKA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Oruka Therapeutics is a clinical-stage biopharmaceutical company working on monoclonal antibody treatments for psoriasis and related inflammatory and immunology conditions. Its work centers on a set of drug candidates aimed at underlying immune pathways linked to these diseases, with the goal of offering new treatment options to patients affected by them.
The company's pipeline includes ORKA-001, aimed at the p19 subunit of interleukin-23 and currently in a phase 2a trial for psoriasis, and ORKA-002, which targets both interleukin-17A and interleukin-17F and is being tested in a phase 2 trial for psoriasis, psoriatic arthritis, and other conditions. It is also developing ORKA-003, aimed at a pathway that has not been disclosed, along with ORKA-021, a regimen that combines ORKA-002 and ORKA-001 in sequence.
Oruka Therapeutics is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ under the ticker ORKA.
Oruka Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.2, in the Neutral zone, down 0.3 points over five sessions.
Down 0.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 43 | +3.1% | +3.6% |
| Accumulation | 180 | +0.6% | +0.5% |
| Neutral (current zone) | 413 | +2.6% | +10.8% |
| Distribution | 56 | +1.6% | +13.2% |
| Selling | 10 | −7.5% | −12.0% |
Average ORKA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Oruka Therapeutics trades 2.8% below Gekko Fair Value of $108.36, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Oruka Therapeutics shares are worth, recalculated every trading day.
$108.36
Gekko Fair Value, Nov 14, 2026
2.8% below fair value · About fair value
At the end of Aug 2026 the price was 30.4% below the estimate.
No open-market insider purchases were filed for Oruka Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ORKA in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ORKA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
2of the funds Gekko tracks hold ORKA.
Oruka Therapeutics reports on Mar 11, 2027 (116 days away), and beat the EPS estimate in 5 of its last 8 reports.
Mar 11, 2027
116 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.55 est −$0.51 | — | +5.9% |
| May 13, 2026 | −$0.48 est −$0.54 | — | −1.2% |
| Mar 12, 2026 | −$0.45 est −$0.62 | — | +16.2% |
| Nov 12, 2025 | −$0.55 est −$0.56 | — | −6.5% |
| Aug 11, 2025 | −$0.46 est −$0.48 | — | +6.6% |
| May 14, 2025 | −$0.40 est −$0.44 | — | −1.7% |
| Mar 6, 2025 | −$0.54 est −$0.41 | — | +0.8% |
| Nov 13, 2024 | −$1.46 est −$0.32 | — | −8.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Oruka Therapeutics is $156.17, +48.2% from the last close, from 12 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 12 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Stifel Nicolaus | $150 | +42.4% |
| Nov 10 | Piper Sandler | $180 | +70.9% |
| Nov 10 | H.C. Wainwright | $120 | +13.9% |
| Nov 10 | Barclays | $160 | +51.9% |
| Nov 10 | UBS | $130 | +23.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Oruka Therapeutics averaged +0.2% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.1% | 3 of 5 |
| Next 10 trading days | −2.6% | 3 of 5 |
| Next 15 trading days | −0.7% | 3 of 5 |
| Next 20 trading days | +0.2% | 3 of 5 |
| Next 30 trading days | −3.2% | 2 of 5 |
For scale, ORKA’s typical 20-trading-day move in either direction is about 7.8%.
Oruka Therapeutics’s market cap is $7.15B and revenue of $0 over the last twelve months.
2 headlines about Oruka Therapeutics from the past week, newest first, each linking to the publisher.
Oruka Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Oruka Therapeutics’s market cap is $7.15B at the Nov 13, 2026 close of $105.35, with 67.82M shares outstanding.
The consensus analyst 12-month price target for Oruka Therapeutics is $156.17, +48.2% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Oruka Therapeutics is about fair value: the Nov 13, 2026 close of $105.35 is 2.8% below Gekko Fair Value of $108.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Oruka Therapeutics is expected to report on Mar 11, 2027 (116 days away). Analysts expect earnings of −$0.78 per share. Oruka Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 5.9% on average across the report.
Oruka Therapeutics’s 52-week high is $115.52 and its 52-week low is $25.23; it closed at $105.35 on Nov 13, 2026, +272.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.